Publications by authors named "Alex T Freedenberg"
Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.
Crit Care Med
July 2021
Article Synopsis
- The study aimed to evaluate the effectiveness of convalescent plasma in increasing antibodies and improving outcomes for COVID-19 patients compared to standard plasma.
- Conducted as a double-blind randomized controlled trial at a New York hospital, 74 patients with confirmed COVID-19 were assigned to receive either convalescent plasma or standard plasma.
- Results showed convalescent plasma increased SARS-CoV-2 antibodies by 14.4%, while standard plasma decreased it by 8.6%; however, both groups had similar rates of ventilator-free days, indicating no significant improvement in primary outcomes.
Background: Convalescent plasma is undergoing randomized trials as a potential therapeutic option for COVID-19 infection. Little empirical evidence exists regarding the determination of donor eligibility and experiences with donor selection.
Study Design And Methods: This prospective study was conducted at a tertiary care hospital in New York to select plasma donors for a randomized, double-blind, controlled convalescent plasma trial.
Background: There are limited data on the neutralizing activity of convalescent plasma (CP) administered in randomized controlled trials (RCT) of COVID-19 infection.
Study Design And Methods: As part of an RCT, CP was collected per FDA guidelines from individuals recovered from COVID-19 infection. CP donors had to have ≥145 optical density (OD) units (ideal target ≥300) using a semiquantitative, immunochromatographic test for IgG antibody to the nucleocapsid protein (NP) of SARS-CoV-2 (typical range 0-500 OD units).